[Construction and application of plasmid pVAX-HBVE harboring hepatitis B surface antibody targeted interferon and interleukin 12 genes].
To construct a new gene therapy plasmid that can express both hepatitis B surface antibody(HBsAb) targeted interferon (dsFvα) and human interleukin 12 (hIL-12) genes for the immunotherapy of chronic hepatitis B. The pEE14.1-dsFvα plasmid was digested to obtain dsFvα fragment, and then the fragment was cloned into the upstream of IRES sequence in vector pVAX-IRES-hIL-12 digested by the same enzyme to construct the recombinant expression plasmid pVAX-HBVE. The recombinant plasmid was transiently transfected into the HEK293T cells and the expression of target gene was detected by ELISA. The recombinant plasmid pVAX-HBVE was extracted and injected into the leg muscles of HBV transgenic mice with electroporation delivery. The HBV gene copies were detected by quantitative PCR before and after injection. Enzyme digestion and sequencing analysis showed that the recombinant plasmid pVAX-HBVE was constructed as expected before. ELISA showed that dsFvα gene and IL-12 gene were successfully expressed in the supernatant of transfected cells. The recombinant plasmid pVAX-HBVE (30 μg, once) reduced the HBV gene copy by two orders of magnitude after being injected into transgenic mice. The neo-type immune gene therapy plasmid was successfully constructed, which would provide an alternative for immune gene therapy of chronic hepatitis B.